LaYow Christine Yu

Mrs. LaYow Christine Yu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TKTim Kong
Tim Kong
ALAngelo B. A. Laranjeira
Angelo B. A. Laranjeira
CLChristopher T. Letson
Christopher T. Letson
LYLaYow Christine Yu
LaYow Christine Yu
SLShuyang Lin
Shuyang Lin
SOStephen T. Oh
Stephen T. Oh
Myeloid malignancies are heterogenous disorders characterized by distinct molecular drivers but share convergence of oncogenic signaling pathways and propagation by ripe pro-inflammatory niches. Here, we establish a comprehensive transcriptional atlas across the spectrum of myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML) through RNA-sequencing of 158 primary samples encompassing CD34+ hematopoietic stem/progenitor cells and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant networks of PI3K/AKT/mTOR signalling and NFκB-mediated hyper-inflammation. Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of ribosomal protein S6 kinase A1 (RSK1) suppresses NFκB activation and diminishes pro-inflammatory mediators including tumor necrosis factor (TNF) associated with MPN disease severity and transformation. We further evaluate a therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, currently in Phase 2 development for breast cancer, for use in myeloid malignancies. Treatment with PMD-026 suppressed disease burden across seven syngeneic and patient-derived xenograft leukemia mouse models spanning the spectrum of driver and disease-modifying mutations. These findings uncover a therapeutic avenue for a conserved dependency across MPN and sAML.

1 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
SMStephanie Michelle Mueller
Stephanie Michelle Mueller
NMNalani Miller
Nalani Miller
JGJasleen Gill
Jasleen Gill
LYLaYow Christine Yu
LaYow Christine Yu
MPMichael Drake Pike
Michael Drake Pike
DODennis P. Orgill
Dennis P. Orgill
(1) Background: Wound healing is a highly coordinated process encompassing hemostasis, inflammation, angiogenesis, keratinocyte migration, collagen deposition, and extracellular matrix remodeling. Successful repair also requires adequate nutrient and oxygen delivery through a well-developed vascular supply. Disruption of these processes can occur through aberrations in diverse biological pathways, including extracellular matrix organization, cellular adhesions, angiogenesis, and immune regulation. (2) Methods: We reviewed mechanisms of impaired tissue repair in monogenic disorders by focusing on three categories—connective tissue, hematological/immunological, and aging-related disorders—to illustrate how single-gene defects disrupt inflammation, cellular proliferation, and matrix remodeling. Additionally, we reviewed various polygenic disorders—chronic kidney disease, diabetes mellitus, hypertension, and obesity—to contrast complex multifactorial pathologies with single-gene defects. (3) Results: This review establishes that genetic impediments, despite their distinct etiologies, monogenic and polygenic disorders share critical downstream failures in the wound healing cascade. While monogenic diseases illustrate direct causal links between specific protein deficits and repair failure, polygenic diseases demonstrate how multifactorial stressors overwhelm the body’s regenerative capacity. (4) Conclusions: This review synthesizes current evidence on both monogenic diseases and polygenic contributions to impaired wound healing. These findings highlight that genetic susceptibility is a decisive factor in the ability to restore tissue homeostasis. This underscores the profound impact of genetic background on the efficacy of hemostasis, inflammation, and remodeling.

29 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SMStephanie Michelle Mueller
Stephanie Michelle Mueller
LYLaYow Christine Yu
LaYow Christine Yu
MPMichael Drake Pike
Michael Drake Pike
HSHannah Shi
Hannah Shi
DODennis P. Orgill
Dennis P. Orgill
Background: Irrigation is a key strategy in reducing bioburden, disrupting biofilms, and supporting wound healing. While saline is the standard for its safety and availability, antiseptic and antibiotic solutions are often used in clinical scenarios that require infection control. However, the rise in antibiotic stewardship and concerns regarding cytotoxicity are reshaping current practices. This review identifies recent trends, current controversies, and persistent gaps in knowledge that warrant further investigation and regulatory attention. Methods: A literature review identified irrigation solutions commonly used in plastic surgery; labeling and concentrations were obtained from Devices@FDA, Drugs@FDA, and DailyMed, and PubMed, Cochrane Central, and Embase were searched (January 2022–July 2025) for human studies on acute wounds, chronic wounds, and implant-based breast surgery. Results: In acute wounds, saline and potable tap water effectively prevent infection. In chronic wounds, such as diabetic foot ulcers and pressure injuries, antiseptic agents, including hypochlorous acid, sodium hypochlorite, polyhexanide, and citrate-based solutions, have shown promise in improving healing and reducing infection. In implant-based breast reconstruction and augmentation, data on antiseptics, such as chlorhexidine, and changes in FDA guidance for povidone–iodine and bacitracin have prompted a reevaluation of intraoperative irrigation practices. Conclusion: Despite widespread use, many antiseptics remain off-label, and high-quality clinical studies comparing efficacy and safety are lacking.

23 June 2026 in Blood
Verified
Journal Article
Open access
FHFan He
Fan He
SLShuyang Lin
Shuyang Lin
TKTim Kong
Tim Kong
DFDaniel A.C. Fisher
Daniel A.C. Fisher
AKAlexander Kim
Alexander Kim
SOStephen T. Oh
Stephen T. Oh
Dysregulation of galectins and global protein glycosylation have been reported in various cancers, but their role in myeloproliferative neoplasms (MPNs) have remained incompletely understood. We performed single-cell RNA sequencing (scRNA-seq) which revealed significant enrichment of galectin genes in MPN monocytes. Cell-cell communication analysis predicted monocytes as a pivotal mediator of cell interactions and galectin signaling as a robust input/output pathway for monocytes. We identified elevated expression of galectin-1 (Gal-1, LGALS1) in monocytes from both human MPN samples and mouse models. Mass cytometry (CyTOF) profiling of MPN blood samples demonstrated that recombinant galectin-1 (rGal-1) significantly increased levels of multiple inflammatory cytokines in monocytes without affecting other cell types. Incubation of CD14+ monocytes from MPN patients with rGal-1 led to markedly increased transcription and secretion of inflammatory cytokines. Mechanistically, we uncovered crosstalk between the TLR4 and Gal-1 signaling pathways, as evidenced by protein 3D modeling and co-immunoprecipitation. Notably, TLR4 inhibition abrogated Gal-1 mediated proinflammatory effects in monocytes. We further identified NF-κB-dependent signaling as a key downstream effector of Gal-1, as reporter assays demonstrated rGal-1 mediated activation of NF-κB signaling in a TLR4-dependent manner. We corroborated these findings in vivo in a murine model driven by MPLW515L in which genetic abrogation of Lgals1 ameliorated key MPN disease features, including leukocytosis and splenomegaly. Additionally, Gal-1 inhibition suppressed carrageenan-induced thrombosis and inflammation in vivo. In summary, we identify Gal-1 enrichment in MPN monocytes as a driver of monocyte-mediated inflammation through TLR4 and NF-κB activation and uncover a novel therapeutic avenue for MPNs.

1 March 2026 in OTA International
Verified
Journal Article
Open access
JHJason Shih Hoellwarth
Jason Shih Hoellwarth
LYLaYow Christine Yu
LaYow Christine Yu
TDTyler D. BA DeSena
Tyler D. BA DeSena
JWJidapa Wongcharoenwatana
Jidapa Wongcharoenwatana
TRTaylor James Reif
Taylor James Reif
SRS. Robert Rozbruch
S. Robert Rozbruch
Objective: The aim of this study was to describe outcomes of osseointegration in amputees with diabetes mellitus (DM) and/or peripheral vascular disease (PVD). Design: This was a case series. Setting: The study was conducted at an urban tertiary referral academic medical center. Patients/Participants: Five patients (1 with DM, 3 with PVD, 1 with both; 4 transtibial, 1 transfemoral) with a follow-up duration of 4.1 ± 0.3 (3.6–4.3) years were included. Intervention: Revision amputation with press-fit osseointegration implant insertion was performed. Main Outcome Measurements: Primary outcomes included adverse events requiring nonsurgical or surgical intervention. Secondary outcomes included patient-reported outcome measures (PROMs) and mobility performance. Results: No patients experienced implant loosening, periprosthetic fracture, procedure-related systemic complications, or death. Three patients received additional surgery: one had osteomyelitis, prompting debridement after 9 months; 2 underwent refashioning to reduce redundant skin around the portal site at 4 years. All PROMs improved significantly. All patients improved by at least one K-level. Conclusion: Osseointegration appears safe to consider for appropriately selected patients with DM and/or PVD. Only one patient had an infection, requiring surgical debridement. The 2 refashioning cases were not infected and may have been avoidable with more aggressive tissue reduction at index surgery. No deaths or systemic complications occurred. Conscientious use and study of osseointegration may help optimize rehabilitation for amputees with DM and/or PVD.

23 April 2025 in OTA International
Verified
Journal Article
Open access
LYLaYow Christine Yu
LaYow Christine Yu
TDTyler D. BA DeSena
Tyler D. BA DeSena
ABAlissa J. Burge
Alissa J. Burge
SRS. Robert Rozbruch
S. Robert Rozbruch
TRTaylor J. Reif
Taylor J. Reif
JHJason S. Hoellwarth
Jason S. Hoellwarth
Objective: This investigation of the safety of titanium transcutaneous osseointegrated nail (TiTON) implants in a magnetic resonance imaging (MRI) suite evaluated whether any adverse events occurred for patients (pain, heating sensation, implant loosening, and delay in care) or for the MRI machine (device damage). Design: Retrospective chart review. Setting: Academic medical center specializing in musculoskeletal health in Manhattan. Patients/Participants: Patients who had osseointegration surgery underwent retrospective chart review and were also contacted inquiring whether they had subsequent MRI to any body part. Thirty-four patients had 51 total MRI scans: 24 of the osseointegrated limb and 27 of other anatomy. Intervention: 1.5T or 3.0T MRI after TiTON implantation. Main Outcome Measurements: Patients were asked if any adverse experiences such as pain, heating sensation, or implant loosening occurred. All original MRI and reports were sought to evaluate for evidence of adverse patient or machine events. Results: No patients had any recognizable adverse event associated with MRI, including specifically pain, heating sensation, or implant loosening. No evidence of adverse machine interaction could be identified. Conclusions: MRI is safe for patients with press-fit TiTON implants. To optimally ensure safety, osseointegrated patients seeking MRI should confirm with their implant company that no nontitanium components might be part of their total prosthesis construct and confirm they have no after-market modifications that may be ferromagnetic, such as screws or clamps.